Bluebee, a leading provider of high-performance genomics analysis and storage solutions and MediSapiens, a leading biomedical big data curation, management and interpretation company, announce a strategic partnership to provide customers with tailored end-to-end analytical solutions for Next Generation Sequencing data.
Sequencing technology is maturing and being optimized for performance, while becoming increasingly affordable. This has opened an era of reliable and foreseeable quality data growth, which demands high computational resources and data storage capabilities to be combined with best in class data interpretation tools. MediSapiens' Explorer™ Platform is now integrated with the Bluebee® platform, offering researchers and clinicians the ability to efficiently curate, analyze, store, interpret and securely share data and findings with colleagues, and use this data efficiently in e.g. personalized medicine initiatives, drug development and cohort or population research. The result is a seamlessly combined workflow, from raw sequencing reads to endpoint analyses.
"With the combination of Bluebee's private cloud based robust and scalable platform for high-speed, configurable data analysis and Explorer™ Platform's capabilities in data curation, management and interpretation, scientists and clinicians now have a comprehensive integrated solution that will enhance the development of new diagnostics in the research lab and enable improved therapeutic decisions in a clinical setting", commented Hans Cobben, CEO of Bluebee.
"For several years, MediSapiens has developed various data interpretation solutions and digital offerings based on its Explorer™ Platform. Bluebee's unique capabilities in optimized and secure genomics pipelines fully complement MediSapiens' integrated biomedical data solutions. This partnership enables us to offer world-class end-to-end solutions for customers working with NGS and offer convenient and powerful tools for pharmaceutical and diagnostic development as well as translational, biobank, cohort and population research", said Sami Kilpinen, CEO of MediSapiens.
